Cerebral palsy (CP) is the leading cause of long-term childhood disability with lifetime societal and economic costs.1 Without a cure for CP, efforts have focused on prevention and on improving function. International guidelines for early detection and intervention for CP were recently published.2 Our institution implemented these recommendations in 2015, earlier than most clinical efforts worldwide. After publication of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) clinical trial,3 The American College of Obstetricians and Gynecologists advised implementing institutional policies for magnesium sulfate administration before anticipated early preterm birth to reduce risk of CP.4 Although BEAM did not show a reduction in the primary outcome (composite of stillbirth, infant death, and moderate or severe CP), rates of moderate or severe CP were reduced among survivors.3 If effective, implementing this recommendation at an institutional level in 2009 should have resulted in fewer subsequent cases of moderate or severe CP at our institution.
Stetson BT, Buhimschi CS, Kellert BA, Hay K, Buhimschi IA, Maitre NL. Comparison of Cerebral Palsy Severity Between 2 Eras of Antenatal Magnesium Use. JAMA Pediatr. 2019;173(2):188–190. doi:10.1001/jamapediatrics.2018.3827
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: